Compare BRTX & AIDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRTX | AIDX |
|---|---|---|
| Founded | 1997 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1M | 2.9M |
| IPO Year | 2015 | 2025 |
| Metric | BRTX | AIDX |
|---|---|---|
| Price | $1.52 | $0.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 22.6K | ★ 208.0K |
| Earning Date | 11-24-2026 | 11-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.48 |
| EPS | ★ N/A | N/A |
| Revenue | $81,000.00 | ★ $2,045,133.00 |
| Revenue This Year | N/A | $44.20 |
| Revenue Next Year | $383.87 | $95.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 16.71 |
| 52 Week Low | $0.14 | $0.18 |
| 52 Week High | $28.99 | $18.96 |
| Indicator | BRTX | AIDX |
|---|---|---|
| Relative Strength Index (RSI) | 41.96 | 28.39 |
| Support Level | $1.32 | N/A |
| Resistance Level | $2.93 | $0.27 |
| Average True Range (ATR) | 0.14 | 0.03 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 53.07 | 16.65 |
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.